Public disclosure of inside information according to article 17 MAR

Biofrontera AG: European Commission extends Ameluz® approval to basal cell carcinoma

Leverkusen (pta032/30.01.2017/16:45 UTC+1) Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, announces today that the European Commission has followed the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and has granted approval extension for Ameluz® to basal cell carcinoma. The extended approval includes the treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults.

The Management Board


Emitter: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Contact Person: Investor & public relations
Phone: +49 (0) 214 87 63 20
ISIN(s): DE0006046113 (Share)
Stock Exchange(s): Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart, Tradegate